Olima Ventures

Olima Ventures is a New York-based early-stage venture capital firm founded in 2009 by Vijay Pandurangan, an engineer-entrepreneur-investor whose operating background includes senior engineering leadership at Twitter and the founding of Ephla Bio, a biotech company developing therapeutics targeting B-cell pathologies. Olima's thesis is to invest early in great teams creating a 'frictionless future,' concentrating in biotech, B2B software, enterprise technology, distributed systems, machine learning, privacy and security, and remote collaboration. The firm also leads biotech incubations directly, reflecting Pandurangan's scientific depth alongside his technology background. Olima writes checks ranging from $100,000 to $5 million with a sweet spot around $1.5 million, covering pre-seed, seed, and Series A stages. Across more than 15 years of deployment the firm has built a portfolio of approximately 68 companies. One portfolio company, Pilot — a bookkeeping and financial-operations platform — achieved unicorn status in 2021, four years after Olima's initial investment. Other notable positions include SpaceX, Candid — a dental aligners company — and Dieta, which was acquired by Cylinder Health in March 2025. The firm operates with a lean team of two to ten professionals. Olima's founder-operator profile is central to its value proposition: Pandurangan's own experience building at Twitter and in biotech gives the firm informed judgment on both the technical and commercial dimensions of early-stage companies. The combination of software and biotech competency under one roof is unusual at the pre-seed and seed stages and allows Olima to serve a broader range of founder types than most comparably-sized funds.